Norsk Hydro, A.s.

Bernt Borretzen

John M Dornish

Rolf O Larsen

Erik O Pettersen

Reidar Oftebro

Harald Breivik

Thomas Ramdahl

Hans Einar Krokan

Knut Helkangs Dahl

Reider Oftebro

Kaare H Bonaa

Rolf Oftebro

Erick O Pettersen

Fatty acid composition comprising at least 80% by weight of omega-3-fatty acids, salts or derivatives thereof, wherein (all-Z)-5,8,11,14,17-eicosapentaenoic acid (EPA) and (all-Z)-4,7,10,13,16,19-docosahexaenoic acid comprises at least 75% by weight of the total fatty acids. The compositions can be used for the treatment or prophylaxis of multiple risk factors for cardiovascular diseases.

Fatty acid composition

New compounds having the general formula I ##STR1## wherein Y may be H or D; and A is H, D, alkyl with 1-4 C-atoms, halogen, nitro, amino, monoalkyl amino or dialkyl amino wherein the alkyl groups have 1-4 C atoms or OR wherein R is H or alkyl of 1-4 C-atoms;

Acetal derivatives of aromatic aldehydes

New compounds of formula I: ##STR1## wherein Y may be CN or ##STR2## wherein A may be H, D, alkyl with 1-4 carbon atoms, OR wherein R is H or alkyl with 1-4 carbon atoms, or --NR.sub.1 R.sub.2 or --CR.sub.1 R.sub.2 R.sub.3 wherein R.sub.1, R.sub.2 and R.sub.3 are the same or different and are H or alkyl with 1-4 carbon atoms;

Deuterated benzaldehydes

Deuterated aromatic aldehydes of the formula: ##STR1## where Ar is substituted phenyl, and derivatives thereof represented by the formula: ##STR2## where Ar is substituted or unsubstituted phenyl, and X.sub.1 and X.sub.2 are substituted hetero atoms or together with the carbon to which they are attached form a heterocycle. These compounds are useful as anticancer and analgesic agents.

Deuterated compounds

The use of L-ascorbic acid, or a pharmaceutically acceptable salt thereof, in combination with 5,6-O-benzylidene-L-ascorbic acid, or 5,6-O-benzylidene-L-ascorbic acid deuterated at least at the 1-position of the aldehyde group of the benzylidene moiety, or a pharmaceutically acceptable salt of such acids, results in a synergistically enhanced cytotoxicity on human carcinoma cells.

Pharmaceutical compositions with anti-cancer activity against carcinoma

Anti-cancer platinum complexes such as cisplatin exhibit a synergistically higher level of anti-tumour activity when administered substantially simultaneously either with L-ascorbic acid, or with 5,6-O-benzylidene-L-ascorbic acid or deuterated forms thereof.

Pharmaceutical compositions with anit-cancer activity and method for the

Anti-cancer platinum complexes such as cisplatin exhibit a synergistically high level of anti-tumor activity when administered substantially simultaneously either with L-ascorbic acid, or with 5,6-O-benzylidene-L-ascorbic acid or deuterated forms thereof.

Pharmaceutical compositions with anti-cancer activity and method for the

Activity against carcinoma and method for the treatment of carcinoma

Deuterated aromatic aldehydes of the formula: ##STR1## where Ar is substituted phenyl, and derivatives thereof represented by the formula: ##STR2## where Ar is substituted or unsubstituted phenyl, and X.sub.1 and X.sub.2 are substituted hetero atoms or together with the carbon to which they are attached from a heterocycle. These compounds are useful as anticancer agents.

Growing community of inventors

Porsgrunn, Norway

Bernt Borretzen